Search Results

Prostate cancer becomes most common cancer among men in South Korea, Lu-177 PSMA therapy reaches cumulative 200 procedures

Prostate cancer incidence in South Korea has continued to rise, making it the most common cancer among men in the country. Meanwhile, a novel nuclear medicine treatment for metastatic prostate cancer—Lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand therapy—is accumulating more clinical cases. Seoul St. Mary's Hospital Uro-Oncology Center stated on September 1 that since performing South Korea's first Lu-177 PSMA treatment on November 2, 2020, the center had administered a cumulative total of 200 such treatments to 84 patients with metastatic prostate cancer as of the 21st of last month. Metastatic castration-resistant prostate cancer refers to a state in which prostate cancer continues to progress despite androgen suppression therapy. As the disease advances, patients have fewer treatment options and a worse prognosis, making it essential to select appropriate treatment modalities and sequencing based on prior treatment history and physical condition.

2026-09-02

Ionetix begins routine supply of astatine-211 in North America, expanding sources of isotopes for targeted alpha therapy

Ionetix, a U.S. medical isotope producer, recently announced that it has begun routine supply of astatine-211 (At-211) in North America. The company stated that this development expands the supply sources of At-211 and is expected to support its further application in preclinical research and clinical development. Ionetix noted that it believes it is the first non-academic commercial supplier of At-211 in the United States. Ionetix produces At-211 at its facility in Lansing, Michigan, leveraging its proprietary cyclotron technology. The company currently operates a 30 MeV cyclotron equipped with optimized target technology, aiming to support the production of clinical-grade At-211. The company stated that its production ca...

2026-09-02

FDA Grants Breakthrough Therapy Designation to JBS-003 for Guiding De-escalated Radiotherapy in HPV-Positive Oropharyngeal Cancer

On September 1, Juniper Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its hypoxia tracer JBS-003. The product, 18F-Fluoromisonidazole (FMISO), is intended to identify tumor hypoxia and guide de-escalated radiotherapy in patients with HPV-positive oropharyngeal cancer (OPC). JBS-003 is licensed from Memorial Sloan Kettering Cancer Center (MSK). According to information released by the company, the tracer is based on F-MISO PET molecular imaging technology and can visualize specific hypoxic features within tumors. Tumor hypoxia is considered to be associated with radioresistance; by imaging hypoxic regions, clinicians can stratify patients by risk and...

2026-09-02

Putin Says Unit 1 of Turkey's Akkuyu Nuclear Power Plant Expected to Start in 2026

Russian President Vladimir Putin stated that he believes Rosatom can start Unit 1 of Turkey's Akkuyu Nuclear Power Plant as scheduled in 2026. According to relevant information, Putin arrived in Kyrgyzstan on August 31 to attend the Shanghai Cooperation Organization summit. On September 1, he held talks with Turkish President Recep Tayyip Erdogan. During the talks, the two sides mentioned cooperation in the energy sector, with the Akkuyu Nuclear Power Plant project being a key focus. Putin stated that the two countries' major joint projects are still progressing, including the well-known Akkuyu Nuclear Power Plant...

2026-09-02

Zhejiang Jinqimen Nuclear Power Unit 1 Pressurizer Relief Tank Successfully Hoisted into Place

On August 30, the pressurizer relief tank, a major nuclear island equipment item of Unit 1 at Zhejiang Jinqimen Nuclear Power Plant, contracted by China Nuclear Industry Fifth Construction Co., Ltd. (CNF), was successfully hoisted into place. The entire hoisting process was smooth and orderly, with overall safety and quality under control. This hoisting has laid a solid foundation for the subsequent installation of main nuclear island equipment and the construction of the primary loop system. The pressurizer relief tank is an important auxiliary equipment of the reactor coolant system in a nuclear power plant. Its main function is to collect and condense the high-temperature and high-pressure steam discharged from the pressurizer safety valves, ensuring the safe and stable operation of the reactor system. The relief tank hoisted this time is pre-installed equipment in the nuclear island. The main body of the equipment is heavy in weight and large in size, with limited hoisting workspace. After being hoisted into place, it needs to be placed in the nuclear island building for a long period, and subsequent construction will be constrained by space, making it necessary to introduce the equipment precisely within the civil construction window period.

2026-09-02

Japan's Mihama Nuclear Power Station Unit 3 Plans Grid Connection on September 15

Kansai Electric Power announced on September 1, 2026, that work related to the periodic inspection of Unit 3 at Japan's Mihama Nuclear Power Station is progressing as planned. Based on the progress of the inspection and the status of corrective measures for the steam leakage issue in the high-pressure turbine, the unit is scheduled to be connected to the grid on September 15. Unit 3 of Mihama Nuclear Power Station is a pressurized water reactor unit with a rated electrical output of 826 MW and a rated thermal output of 2,440 MW. On May 8 this year, the unit underwent a manual reactor shutdown after steam leakage was confirmed in the high-pressure turbine. From June 16, the unit entered its 29th periodic inspection. Kansai Electric Power stated that, in response to the steam leakage in the high-pressure turbine, the upper cylinder sealing cover has been replaced based on the results of the cause investigation, and multiple measures such as the development of relevant guidelines are being advanced.

2026-09-01

Fourteen academic societies in South Korea call for protection of KRR-1 research reactor auxiliary buildings

On September 1, fourteen academic societies and associations, including the Korean Nuclear Society, issued a statement welcoming the temporary registration of the reactor hall and auxiliary buildings of Research Reactor Unit 1 (KRR-1, TRIGA Mark-II) in Gongneung-dong, Nowon-gu, Seoul, as nationally registered cultural heritage, and urged Korea Electric Power Corporation (KEPCO), the owner of the site and buildings, to promptly submit a formal registration application. Panoramic view of KRR-1, South Korea's first research reactor. Korea National Heritage Administration The Korea National Heritage Administration had placed the KRR-1 reactor hall and auxiliary buildings on the temporary list of nationally registered cultural heritage on July 1 through the emergency measures system, suspending related demolition work. However, if a formal registration application is not submitted by the end of December this year, the temporary listing will lapse and demolition work may resume.

2026-09-01

Beijing Jiluntai's ¹⁷⁷Lu-JLT003 Injection Receives IND Approval for Treatment of Integrin αvβ3-Positive Malignant Tumors

Beijing Jiluntai Pharmaceutical Co., Ltd. has recently achieved progress in radiopharmaceutical R&D. Its self-developed Class 1 innovative therapeutic radiopharmaceutical ¹⁷⁷Lu-JLT003 Injection (generic name: ¹⁷⁷Lu-AB-3PRGD2) has obtained the Clinical Trial Approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), intended for the treatment of integrin αvβ3-positive malignant tumors. ¹⁷⁷Lu-AB-3PRGD2 is a therapeutic radiopharmaceutical targeting integrin αvβ3. Integrin αvβ3 is highly expressed on various solid tumor cells and tumor neovascular endothelial cells, while showing low expression in normal tissues, a characteristic that...

2026-09-01

Bayer Presents Phase III Data for Iodine-124 PET Tracer: High Sensitivity Shown in Cardiac Amyloidosis Diagnosis

At the 2026 European Society of Cardiology Congress, Bayer presented results from the Phase III REVEAL study of its investigational PET radiotracer iodine-124 evuzamitide (I-124 evuzamitide). Data showed that the tracer met the study's primary endpoints in diagnostic sensitivity and specificity when used for imaging in patients with suspected cardiac amyloidosis. The REVEAL study, sponsored by Brigham and Women's Hospital, is a multicenter, open-label, single-arm Phase III clinical trial conducted at 18 sites in the United States, enrolling 170 adult patients with suspected cardiac amyloidosis. Following a single intravenous injection of I-124 evuzamitide, subjects underwent cardiac and...

2026-09-01

Qinshan Nuclear Power Plant Unit 2 Outage 218 Officially Commences

At 2:20 AM on September 1, Unit 2 of Qinshan Phase II was disconnected from the East China Power Grid, marking the official commencement of Outage 218. This outage is a Category C overhaul for Unit 2 of Qinshan Phase II. In addition to the routine annual overhaul items such as reactor coolant system head removal and installation, fuel handling, SG eddy current inspection and flushing, it also includes important special tasks such as generator rotor removal, insertion and inspection, diesel generator excitation system renovation, PSR weakness anti-boron dilution modification, reactor coolant system automatic makeup and residual heat removal eddy current detection function, and nuclear island low-voltage switchgear renovation. The planned items for this outage total 6,119: including 3,764 preventive items, 171 strategic maintenance items, 789 periodic tests, 133 modification work orders, and 1,262 other types of work.

2026-09-01

US TerraPower Awards Additional Natrium Reactor Supplier Contracts

US nuclear innovation company TerraPower announced on August 31 that it has selected 12 suppliers to continue advancing the supply chain for its first Natrium nuclear power plant—Kemmerer Unit 1 in Wyoming, USA. The project is currently under construction, and TerraPower describes it as the first utility-scale advanced reactor project under construction in the Western Hemisphere. Pat Young, Senior Vice President of TerraPower and Director of the Natrium Project, stated that securing supplier contracts is a critical step in building the resilient supply chain needed for advanced nuclear power plant construction. With the signing of these contracts, the company is expanding its network of qualified partners and advancing the key milestones required for Natrium reactor commercialization.

2026-09-01

Defence Therapeutics Expands Radiopharmaceutical R&D Program to Evaluate Alpha and Beta Emitter Applications

MONTREAL, Quebec, Canada — Biotechnology company Defence Therapeutics Inc. recently announced the expansion of its radiopharmaceutical R&D program to include α and β radioisotopes in its evaluation scope, further validating the application potential of its proprietary Accum® technology in precision oncology. Defence Therapeutics is a publicly traded biotechnology company developing next-generation oncology treatments centered on its Accum® precision drug delivery platform. The company stated that the Accum® technology is designed to facilitate the entry of drug payloads into the intracellular compartment, thereby improving delivery efficiency. This expansion of the radiopharmaceutical program...

2026-09-01

US Westinghouse Electric Seeks to Restart Nuclear Expansion via IPO

US nuclear power company Westinghouse Electric Company is seeking to advance its business revival through an initial public offering. The company previously fell into bankruptcy due to project delays and sharp cost overruns in its nuclear projects, and has since undergone changes in ownership. Recently disclosed information shows that Westinghouse Electric submitted a confidential IPO application last July, with the specific listing date and offering size yet to be determined. Market observers believe that growing electricity demand driven by artificial intelligence development, along with the policy environment promoting nuclear power expansion in the US, is improving valuation expectations for nuclear power companies. David Nicholas, CEO of nuclear energy ETF manager Xfunds...

2026-09-01

CNNC Headway's 13C-Urea Synthesis Control Method Patent Wins China Patent Excellence Award

On August 28, the China National Intellectual Property Administration officially released the decision on the 26th China Patent Award, and CNNC Headway's invention patent "A 13C-Urea Synthesis Control Method" won the China Patent Excellence Award. This patented technology addresses key technical bottlenecks in the batch production of carbon [13C]-urea API, establishing a set of synthesis control methods that provide technical support for the large-scale and stable production of the relevant API. The application of this technology helps enhance the self-sufficiency capability of the domestic urea [13C] breath diagnostic industry chain. CNNC Headway has long been deeply engaged in the breath diagnostic field, with sustained investment in innovative R&D, quality control, clinical adaptation, and industry chain layout...

2026-09-01

Korea's Eugene MS Wins KRW 11.4 Billion Order for ITER Core Components

Korea's Eugene MS announced on August 31 that it has signed a contract with the Korea Institute of Fusion Energy (KFE) to produce and supply the second batch of vacuum vessel port sealing flanges for the International Thermonuclear Experimental Reactor (ITER). The contract is valued at approximately KRW 11.4 billion, equivalent to about 44% of Eugene MS's 2025 revenue of KRW 25.9 billion. The contract period runs through December 2030. Under the arrangement, the sealing flanges will be delivered to the ITER Organization in three batches, with final inspection and related procedures scheduled for completion by June 30, 2031. The ITER vacuum vessel port sealing flanges consist of large fasteners and other components...

2026-08-31